Atlas Trials

Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus

Clinical trial NCT06040177 · UNKNOWN

Trial details

NCT number
NCT06040177
Sponsor
First Affiliated Hospital of Guangxi Medical University
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Hepatocellular Carcinoma Non-resectablePortal Vein Tumor ThrombusImmune Checkpoint Inhibitors
Start date
2023-02-02
Primary completion
2023-02-02
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.